Companies › Alkeus Pharmaceuticals
1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 3; Ophthalmology; next expected readout Jun 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ALK-001 Deuterated vitamin A analog that slows production of lipofuscin and related retinoid bypro | LRAT | Phase 3 | Stargardt Disease | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02402660 | ALK-001 | Phase 2 | Stargardt Disease | Ophthalmology | Jun 2028 |
| NCT04239625 | ALK-001 | Phase 2 | Stargardt Disease | Ophthalmology | Dec 2028 |
| NCT07419334 | ALK-001 | Phase 3 | Stargardt Disease | Ophthalmology | Oct 2029 |
–
ReGenTree Ocus Innovation Ireland Ocumension Therapeutics (Suzhou) Laboratorios Sophia S.A de C.V. Cloudbreak Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.